Table 2.
Summary of demographic data – all subjects
| Group | Gender | Race | Statistic | Age (years) | Weight (kg) | Height (cm) | BMI (kg m−2) |
|---|---|---|---|---|---|---|---|
| Placebo (n = 6) | 4 male | 6 White | Mean | 60.5 | 80.5 | 174.8 | 26.22 |
| 2 female | SD | 6.4 | 11.6 | 11.2 | 1.26 | ||
| Range | 50–68 | 65–94 | 160–186 | 25.0–28.1 | |||
| Dose 3.6 mg (n = 6) | 6 female | 6 White | Mean | 59.8 | 65.7 | 165.5 | 23.97 |
| SD | 8.0 | 6.7 | 4.2 | 2.21 | |||
| Range | 50–68 | 60–78 | 158–170 | 22.3–28.3 | |||
| Dose 7.2 mg (n = 7) | 4 male 3 female | 7 White | Mean | 60.9 | 77.9 | 173.0 | 25.97 |
| SD | 8.6 | 10.3 | 11.3 | 1.87 | |||
| Range | 50–72 | 62–92 | 159–186 | 23.8–28.9 | |||
| Dose 10.8 mg (n = 8) | 3 male 5 female | 8 White | Mean | 61.0 | 70.0 | 168.8 | 24.55 |
| SD | 6.7 | 8.3 | 9.8 | 1.63 | |||
| Range | 53–70 | 60–82 | 155–182 | 22.6–27.1 | |||
| Total (n= 27) | 11 male 16 female | 27 White | Mean | 60.6 | 73.4 | 170.5 | 25.16 |
| SD | 7.0 | 10.6 | 9.8 | 1.91 | |||
| Range | 50–72 | 60–94 | 155–186 | 22.3–28.9 |
The cohorts could not be balanced with respect to the ratio of male and female subjects due to randomizations. Both male subjects in cohort 1 (3.6 mg MSF) were randomized to receive placebo, making all the subjects receiving 3.6 mg MSF women only. Of the 27 subjects described above, 22 completed the study (see Figure 1).